The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

Summary

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of KSVCBD injection in AQP4-positive Neuromyelitis Optica Spectrum Disorder

Timeline

Start

2026-05-15

Primary completion

2028-12-31

Completion

2029-03-31

Drugs

Indications